Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 8/20 | 0.56 |
| ▸ | EGFR | P00533 | 12/20 | 0.51 |
| ▸ | ITK | Q08881 | 4/20 | 0.51 |
| ▸ | BTK | Q06187 | 4/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | BLK | P51451 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6492412 | 0.89 | ERBB2 (0.67) | ERBB2EGFRITKBTKSRC | |
| SCHEMBL6482672 | 0.83 | ERBB2 (0.62) | ERBB2EGFRITKBTKSRC | |
| SCHEMBL6483467 | 0.82 | ERBB2 (0.58) | ERBB2EGFRITKBTKSRC | |
| SCHEMBL6494532 | 0.79 | ERBB2 (0.57) | ERBB2EGFRKCNH2ERBB4 | |
| SCHEMBL6483473 | 0.77 | ERBB2 (0.55) | ERBB2EGFRITKBTKSRC | |
| SCHEMBL6484938 | 0.76 | ERBB2 (0.54) | ERBB2EGFRITKBTKERBB4 | |
| SCHEMBL6490706 | 0.76 | ERBB2 (0.66) | ERBB2EGFRITKBTKSRC | |
| SCHEMBL6482142 | 0.76 | ERBB2 (0.59) | ERBB2EGFRERBB4 | |
| SCHEMBL6495527 | 0.74 | ERBB2 (0.52) | ERBB2EGFRERBB4 | |
| SCHEMBL30423263 | 0.74 | EGFR (0.67) | EGFRITKBTKSRCBLK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6881737-B2 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. (US) | 2005-04-19 | — | — | US | claimed |
| EP-1390354-A1 | TRIAZINYL ACRYLAMIDE DERIVATIVES AS KINASE INHIBITORS | Amgen Inc. (US) | 2004-02-25 | — | — | EP | claimed |
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. | 2003-07-24 | — | — | US | claimed |
| WO-2002083653-A1 | TRIAZINYL ACRYLAMIDE DERIVATIVES AS KINASE INHIBITORS | AMGEN INC. (US) | 2002-10-24 | — | — | WO | claimed |
| US-20050176700-A1 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-08-11 | — | — | US | disclosed |
| US-6881737-B2 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. (US) | 2005-04-19 | — | — | US | disclosed |
| EP-1390354-A1 | TRIAZINYL ACRYLAMIDE DERIVATIVES AS KINASE INHIBITORS | Amgen Inc. (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. | 2003-07-24 | — | — | US | disclosed |
| WO-2002083653-A1 | TRIAZINYL ACRYLAMIDE DERIVATIVES AS KINASE INHIBITORS | AMGEN INC. (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | PKD1, PKD2, GLS | ERBB2 440/4885EGFR 228/4885ITK 755/4885 |
| US-20050176700-A1 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases | REN, AGTR1, ACE | ERBB2 2073/4885EGFR 1776/4885ITK 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.